AI-generated summary
The authors conducted a bibliometric analysis of 150 PubMed-indexed studies, including 46 clinical trials, on photobiomodulation for central nervous system disorders up to September 2024. They report positive effects of photobiomodulation on the central nervous system and describe proposed mechanisms, while noting that challenges remain in optimizing wavelengths, light sources and standardized treatment protocols.
- Studies included
- 150
- Who or what was studied
- Central nervous system disorders, including Alzheimer's disease, Parkinson's disease and stroke, as studied in PubMed-indexed studies (including 46 clinical trials) up to September 2024
- Limits stated in the abstract
- The abstract notes heterogeneity in parameters, unresolved optimal wavelengths and protocols, and a lack of robust dose-response relationships.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Adenosine triphosphate, Light-emitting diode, Oxidative stress, Neuromodulation, Heterogeneity, Nitric oxide, Irradiance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.